These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 27714957)

  • 1. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
    Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY
    Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening.
    Ye Y; Zhang B; Mao R; Zhang C; Wang Y; Xing J; Liu YC; Luo X; Ding H; Yang Y; Zhou B; Jiang H; Chen K; Luo C; Zheng M
    Org Biomol Chem; 2017 May; 15(17):3648-3661. PubMed ID: 28397890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations.
    Tao H; Yan X; Zhu K; Zhang H
    Chem Pharm Bull (Tokyo); 2019; 67(4):382-388. PubMed ID: 30930442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
    Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays.
    Ye F; Zhang W; Ye X; Jin J; Lv Z; Luo C
    J Chem Inf Model; 2018 May; 58(5):1066-1073. PubMed ID: 29672052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
    Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W
    J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
    Mao R; Shao J; Zhu K; Zhang Y; Ding H; Zhang C; Shi Z; Jiang H; Sun D; Duan W; Luo C
    J Med Chem; 2017 Jul; 60(14):6289-6304. PubMed ID: 28650658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
    Zhu K; Jiang C; Tao H; Liu J; Zhang H; Luo C
    Bioorg Med Chem Lett; 2018 May; 28(9):1476-1483. PubMed ID: 29628326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
    Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T
    Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
    Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
    Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting protein arginine methyltransferase 5 in disease.
    Richters A
    Future Med Chem; 2017 Nov; 9(17):2081-2098. PubMed ID: 29076773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
    Wang Y; Hu W; Yuan Y
    J Med Chem; 2018 Nov; 61(21):9429-9441. PubMed ID: 29870258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of PRMT5 inhibitors with novel scaffold structures through virtual screening and biological evaluations.
    Zhang Q; Zhang L; Jin J; Fan Y; Wang X; Hu H; Ye X; Wang L; Cao C; Ye F
    J Mol Model; 2022 Jun; 28(7):184. PubMed ID: 35680707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations.
    Zhu K; Tao H; Song JL; Jin L; Zhang Y; Liu J; Chen Z; Jiang CS; Luo C; Zhang H
    Bioorg Chem; 2018 Dec; 81():289-298. PubMed ID: 30172110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel PRMT5 inhibitors bearing a methylpiperazinyl moiety.
    Bai X; Zhai Z; Zhao X; Li R; Liang L; Jin Y; Yin Y
    Future Med Chem; 2022 Jul; 14(14):1071-1086. PubMed ID: 35748226
    [No Abstract]   [Full Text] [Related]  

  • 16. PRMT5 inhibition promotes osteogenic differentiation of mesenchymal stromal cells and represses basal interferon stimulated gene expression.
    Kota SK; Roening C; Patel N; Kota SB; Baron R
    Bone; 2018 Dec; 117():37-46. PubMed ID: 30189247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-yl)anilines Core Identified by Virtual Screening and Biological Evaluation.
    Zhang Y; Zhu K; Zhang J; Zhang JH; Song Z; Zhang X; Liu SK; Jiang CS
    Curr Pharm Des; 2023; 29(6):474-479. PubMed ID: 36790004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation.
    Shao J; Zhu K; Du D; Zhang Y; Tao H; Chen Z; Jiang H; Chen K; Luo C; Duan W
    Eur J Med Chem; 2019 Feb; 164():317-333. PubMed ID: 30605830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
    Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
    Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer.
    Liu S; Liu Z; Piao C; Zhang Z; Kong C; Yin L; Liu X
    J Exp Clin Cancer Res; 2022 Oct; 41(1):293. PubMed ID: 36199122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.